746452
Magnesium sulfate
anhydrous, free-flowing, Redi-Dri™, ReagentPlus®, ≥99.5%
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
MgSO4
CAS 번호:
Molecular Weight:
120.37
NACRES:
NA.21
PubChem Substance ID:
UNSPSC Code:
12352302
EC Number:
231-298-2
MDL number:
Assay:
≥99.5%
Grade:
anhydrous
Form:
powder
grade
anhydrous
Quality Level
agency
suitable for SM 5210
vapor density
<0.01 (vs air)
vapor pressure
<0.1 mmHg ( 20 °C)
product line
ReagentPlus®, Redi-Dri™
assay
≥99.5%
form
powder
quality
free-flowing
pH
~7.9 (25 °C, 50 g/L)
SMILES string
[Mg++].[O-]S([O-])(=O)=O
InChI
1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
InChI key
CSNNHWWHGAXBCP-UHFFFAOYSA-L
General description
Magnesium sulfate is a magnesium salt with tocolytic ability. Its role to induce an analgesic effect during intraoperative and postoperative periods has been investigated. It is reported to prevent eclampsia. Its ability to remove water from water-miscible solvents by salting-out phase separation has been studied.
Application
Magnesium sulfate may be used as a drying agent for organic extracts.
Features and Benefits
- Increased efficiency – Eliminate time and effort of loosening hardened powders
- Safety – Avoid risks of using tools of force to break up clumps
- Economy – Faster preparation and solvation increase productivity and reduce costs
- Assured quality – Excellent, expert-tested quality with no anti-caking agents
- Flexible volumes – Available from research amounts to scale-up quantities
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Redi-Dri is a trademark of Sigma-Aldrich Co. LLC
저장 등급
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
문서
Redi-Dri™ prevents hygroscopic powders, such as inorganic salts, from absorbing moisture and forming clumps, leaving the salts free-flowing every time.
관련 콘텐츠
This page is intended to make it easier to find the consumables you need based on the analytical method you’re using. Methods included on this page come from the EPA, Standard Methods and ASTM.
Lex W Doyle et al.
Obstetrics and gynecology, 113(6), 1327-1333 (2009-05-23)
To systematically review rates of neurologic outcomes reported in childhood for the preterm fetus exposed to antenatal magnesium sulfate. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL (The Cochrane Library 2008, Issue 3), relevant references from retrieved
Lex W Doyle
Current opinion in pediatrics, 24(2), 154-159 (2012-01-10)
Antenatal magnesium sulfate may reduce the excessive rates of cerebral palsy in survivors of very preterm birth. There are five randomized controlled trials of magnesium sulfate therapy given to the mother prior to very preterm birth which have reported neurological
Federica Belluti et al.
ChemMedChem, 9(2), 371-382 (2014-01-10)
A significant improvement in the treatment of trypanosomiases has been achieved with the recent development of nifurtimox-eflornithine combination therapy (NECT). As an alternative to drug combinations and as a means to overcome most of the antitrypanosomatid drug discovery challenges, a
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| 746452-2.5KG | 04061832891231 |
| 746452-6X500G | 04061832891262 |
| 746452-100G | 04061832581071 |
| 746452-12KG | 04061838351876 |
| 746452-4X2.5KG | 04061832891248 |
| 746452-500G | 04061832891255 |
| 746452-6X1KG | 04061832581088 |
| 746452-1KG | 04061832891217 |